---
title: "Leqvio (inclisiran), all indications: Pharmacology questions"
description: "Pharmacology questions on Leqvio (inclisiran) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: What type of drug is Leqvio (siRNA)? How does Leqvio work (mechanism of action)? Does Leqvio change DNA? How long does Leqvio stay in the blood (half-life)? 2 further questions follow. 6 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/leqvio/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Leqvio (inclisiran), all indications: Pharmacology questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Leqvio](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf)  
Indication pages: [Hypercholesterolemia](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia)

## Mechanism

<a id="leqvio-drug-class"></a>

### What type of drug is Leqvio (siRNA)?

> “LEQVIO contains inclisiran sodium, a small interfering RNA (siRNA) directed to proprotein convertase 
> subtilisin kexin type 9 (PCSK9) mRNA.”

Source: [LEQVIO: Prescribing information, page 6, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=6)

<a id="leqvio-mechanism"></a>

### How does Leqvio work (mechanism of action)?

> “LEQVIO prevents formation of PCSK9 protein, allowing more LDL-C receptors to remove circulating LDL-C<sup>1</sup>”

Source: [LEQVIO: Mechanism of Action | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/mechanism-of-action#:~:text=LEQVIO%20prevents%20formation%20of%20PCSK9,LDL%2DC%20receptors%20to%20remove%20circulating)

> “Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA), conjugated on the sense strand with 
> triantennary N-Acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes. In hepatocytes, inclisiran 
> utilizes the RNA interference mechanism and directs catalytic breakdown of mRNA for PCSK9. This increases 
> LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and 
> lowers LDL-C levels in the circulation.”

Source: [LEQVIO: Prescribing information, page 7, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=7)

> “Inclisiran has been shown to have high uptake into, and selectively for the liver, the target organ for 
> cholesterol lowering.”

Source: [LEQVIO: Prescribing information, page 7, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=7)

<a id="leqvio-dna"></a>

### Does Leqvio change DNA?

> “Harnesses the body’s process of RNA interference, which is restricted to the cytoplasm<sup>2,3</sup>
> No impact on DNA<sup>2,3</sup>”

Source: [LEQVIO: Mechanism of Action | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/mechanism-of-action#:~:text=Harnesses%20the%20body%E2%80%99s%20process%20of,No%20impact%20on)

Note: The page attributes these statements to published literature on RNA interference therapeutics (Khvorova, N Engl J Med 2017; Fitzgerald et al., N Engl J Med 2017).

## Pharmacokinetics

<a id="leqvio-half-life"></a>

### How long does Leqvio stay in the blood (half-life)?

> “Concentrations reached undetectable levels after 24 to 48 hours post dosing.”

Source: [LEQVIO: Prescribing information, page 7, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=7)

> “The terminal elimination half-life of LEQVIO is approximately 9 hours, and no accumulation occurs with 
> multiple dosing.”

Source: [LEQVIO: Prescribing information, page 7, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=7)

> “At Day 
> 180, LDL-C levels were still reduced by approximately 53%.”

Source: [LEQVIO: Prescribing information, page 7, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=7)

Note: The first two passages describe plasma concentrations of inclisiran. The third is from the pharmacodynamics section and describes LDL-C after a single 284 mg dose.

<a id="leqvio-metabolism"></a>

### How is Leqvio metabolized and cleared from the body?

> “Inclisiran is primarily metabolized by nucleases to shorter nucleotides of varying length. Inclisiran is not a 
> substrate for CYP450 or transporters.  
> Excretion  
> Approximately 16% of LEQVIO is cleared through the kidney.”

Source: [LEQVIO: Prescribing information, page 8, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=8)

## Components

<a id="leqvio-inactive-ingredients"></a>

### What are the inactive ingredients in Leqvio?

> “LEQVIO is a sterile, preservative-free, clear, and colorless to pale yellow solution for subcutaneous use in a 
> prefilled syringe. Each syringe contains 1.5 mL of solution containing the equivalent of 284 mg inclisiran”

Source: [LEQVIO: Prescribing information, page 6, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=6)

> “(present as 300 mg inclisiran sodium salt). LEQVIO is formulated in Water for Injection and may also contain 
> sodium hydroxide and/or phosphoric acid for pH adjustment to a target pH of 7.0.”

Source: [LEQVIO: Prescribing information, page 7, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=7)

## Related pages
- [Medical information: Leqvio (inclisiran): All indications](https://www.evicenter.com/medical-information/leqvio)
- [Indication](https://www.evicenter.com/medical-information/leqvio/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/leqvio/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/leqvio/safety)
- [Specific populations](https://www.evicenter.com/medical-information/leqvio/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/leqvio/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/leqvio/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/leqvio/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/leqvio/access-and-coverage)
